tanshinone has been researched along with celastrol in 2 studies
| Studies (tanshinone) | Trials (tanshinone) | Recent Studies (post-2010) (tanshinone) | Studies (celastrol) | Trials (celastrol) | Recent Studies (post-2010) (celastrol) |
|---|---|---|---|---|---|
| 1,445 | 10 | 1,033 | 885 | 1 | 741 |
| Protein | Taxonomy | tanshinone (IC50) | celastrol (IC50) |
|---|---|---|---|
| Telomerase reverse transcriptase | Homo sapiens (human) | 0.78 | |
| Ubiquitin carboxyl-terminal hydrolase 2 | Homo sapiens (human) | 6.8 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L1 | Homo sapiens (human) | 6.8 | |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 8.41 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L3 | Homo sapiens (human) | 6.8 | |
| Tyrosine-protein phosphatase non-receptor type 1 | Homo sapiens (human) | 3.45 | |
| Tyrosine-protein phosphatase non-receptor type 6 | Homo sapiens (human) | 3.1 | |
| Tyrosine-protein phosphatase non-receptor type 11 | Homo sapiens (human) | 3.5667 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 0.25 | |
| Regulator of G-protein signaling 17 | Homo sapiens (human) | 6.1795 | |
| Ubiquitin carboxyl-terminal hydrolase 15 | Homo sapiens (human) | 6.8 | |
| Ubiquitin carboxyl-terminal hydrolase isozyme L5 | Homo sapiens (human) | 6.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
| Chang, YH; Hung, HY | 1 |
1 review(s) available for tanshinone and celastrol
| Article | Year |
|---|---|
Recent advances in natural anti-obesity compounds and derivatives based on in vivo evidence: A mini-review.
Topics: Animals; Anti-Obesity Agents; Drug Discovery; Obesity; Phytochemicals | 2022 |
1 other study(ies) available for tanshinone and celastrol
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |